TGTX
TG Therapeutics, Inc.stockNASDAQ
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 63.38 | 2026-11-09 | +0.38% | 1.480 |
| 1M | 53.97 | 2026-10-16 | +17.88% | 1.098 |
| 3M | 49.28 | 2026-08-17 | +29.10% | 0.951 |
| 6M | 39.50 | 2026-05-15 | +61.06% | 0.320 |
| 1Y | 30.69 | 2025-11-17 | +107.30% | 0.677 |
| 2Y | 29.54 | 2024-11-15 | +115.37% | — |
| 5Y | 26.64 | 2021-11-16 | +138.81% | 1.750 |
TG Therapeutics, Inc. (NASDAQ:TGTX) stock price today is $63.62, and today's volume is 248,529. TGTX is down 1.380% today. The 30 day average volume is 1.91M. TGTX market cap is $9.62B with 151.15M shares outstanding.
